...
首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Effects of Modified Simiao Decoction on IL-1/3 and TNFa Secretion in Monocytic THP-1 Cells with Monosodium Urate Crystals-Induced Inflammation
【24h】

Effects of Modified Simiao Decoction on IL-1/3 and TNFa Secretion in Monocytic THP-1 Cells with Monosodium Urate Crystals-Induced Inflammation

机译:加味四妙汤对尿酸一钠晶体诱导炎症的单核细胞THP-1细胞IL-1 / 3和TNFa分泌的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Simiao pill, a Chinese herbal formula containing four herbs, has been used in the treatment of gouty arthritis for many years. The aim of this study was to explore the effects of modified Simiao decoction (MSD) on IL-lj3 and TNFa secretion in monocytic THP-1 cells with monosodium urate (MSU) crystals-induced inflammation. The MSU crystals-induced inflammation model in THP-1 cells was successfully established by the stimulation of phorbol 12-myristate 13-acetate (PMA) and MSU crystals. Then, the MSD-derived serum or control serum extracted from rat was administered to different treatment groups. The morphology of MSU crystals and THP-1 cells was observed. IL-1/3 and TNFa protein expression in supernatant of THP-1 cells were determined by ELISA. Our data demonstrated that MSU crystals induced time-dependent increase of IL-ljS and TNFa. Moreover, MSD significantly decreased IL-ljS release in THP-1 cells with MSU crystals-induced inflammation. These results suggest that MSD is promising in the treatment of MSU crystals-induced inflammation in THP-1 cells. MSD may act as an anti-IL-1 agent in treating gout. The underlying mechanism may be related to NALP3 inflammasome which needs to be validated in future studies.
机译:包含四种草药的中草药配方思妙丸已被用于治疗痛风性关节炎多年。这项研究的目的是探讨加味四妙汤(MSD)对尿酸一钠(MSU)晶体诱导的炎症的单核THP-1细胞中IL-1j3和TNFa分泌的影响。通过刺激佛波醇12-肉豆蔻酸酯13-乙酸酯(PMA)和MSU晶体,成功建立了MSU晶体在THP-1细胞中诱导的炎症模型。然后,从大鼠提取的MSD来源的血清或对照血清被给予不同的治疗组。观察到MSU晶体和THP-1细胞的形态。 ELISA法检测THP-1细胞上清中IL-1 / 3和TNFa蛋白的表达。我们的数据表明,MSU晶体诱导了IL-1jS和TNFa的时间依赖性增加。此外,MSD显着降低了MSU晶体引起的THP-1细胞中IL-1jS的释放。这些结果表明,MSD在治疗THP-1细胞中MSU晶体诱导的炎症中很有前途。 MSD可作为治疗痛风的抗IL-1药物。潜在的机制可能与NALP3炎性小体有关,需要在以后的研究中进行验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号